Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

RedHill Biopharma (RDHL) EBT Margin: 2009-2024

Historic EBT Margin for RedHill Biopharma (RDHL) over the last 16 years, with Dec 2024 value amounting to -102.80%.

  • RedHill Biopharma's EBT Margin rose 352580.00% to 3,280.68% in Q2 2023 from the same period last year, while for Jun 2023 it was -111.91%, marking a year-over-year increase of 10647.00%. This contributed to the annual value of -102.80% for FY2024, which is 46905.00% down from last year.
  • According to the latest figures from FY2024, RedHill Biopharma's EBT Margin is -102.80%, which was down 128.07% from 366.25% recorded in FY2023.
  • RedHill Biopharma's EBT Margin's 5-year high stood at 366.25% during FY2023, with a 5-year trough of -115.97% in FY2022.
  • In the last 3 years, RedHill Biopharma's EBT Margin had a median value of -102.80% in 2024 and averaged 49.16%.
  • In the last 5 years, RedHill Biopharma's EBT Margin tumbled by 62,142bps in 2020 and then soared by 48,222bps in 2023.
  • RedHill Biopharma's EBT Margin (Yearly) stood at 79.55% in 2020, then plummeted by 19,352bps to -113.98% in 2021, then plummeted by 199bps to -115.97% in 2022, then skyrocketed by 48,222bps to 366.25% in 2023, then slumped by 46,905bps to -102.80% in 2024.